Vol. 6 No. 6 (2026): June
Reimbursement Reviews

Roflumilast (Zoryve)

decorative image of the issue cover

Published June 22, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses roflumilast (Zoryve), 0.15% w/w, topical cream.
  • Indication: For topical treatment of mild to moderate AD in patients 6 years of age and older.